Aerie thinks long term, wants to bring in more drugs

Standing in a small lab space off Kit Creek Road, Casey Kopczynski has big plans. Kopczynski, the chief scientific officer with Aerie Pharmaceuticals (Nasdaq: AERI), and his colleagues are working to bring a glaucoma treatment to market and capture 40 percent of a market they estimate at $5 billion annually...